CN114901267A - 酰化活性剂及其用于治疗代谢障碍和非酒精性脂肪肝病的方法 - Google Patents

酰化活性剂及其用于治疗代谢障碍和非酒精性脂肪肝病的方法 Download PDF

Info

Publication number
CN114901267A
CN114901267A CN202080084735.0A CN202080084735A CN114901267A CN 114901267 A CN114901267 A CN 114901267A CN 202080084735 A CN202080084735 A CN 202080084735A CN 114901267 A CN114901267 A CN 114901267A
Authority
CN
China
Prior art keywords
subject
dosage form
unit dosage
active agent
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080084735.0A
Other languages
English (en)
Chinese (zh)
Inventor
J·P·小凯西
D·A·贝里
T·F·布里格斯
L·巴克宾德
M-J·金
A·梁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Flagship Entrepreneurship And Innovation Co 5
Original Assignee
Flagship Entrepreneurship And Innovation Co 5
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Flagship Entrepreneurship And Innovation Co 5 filed Critical Flagship Entrepreneurship And Innovation Co 5
Publication of CN114901267A publication Critical patent/CN114901267A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/618—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
CN202080084735.0A 2019-12-05 2020-12-04 酰化活性剂及其用于治疗代谢障碍和非酒精性脂肪肝病的方法 Pending CN114901267A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962944282P 2019-12-05 2019-12-05
US62/944282 2019-12-05
US202063074785P 2020-09-04 2020-09-04
US63/074785 2020-09-04
PCT/US2020/063281 WO2021113620A1 (en) 2019-12-05 2020-12-04 Acylated active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease

Publications (1)

Publication Number Publication Date
CN114901267A true CN114901267A (zh) 2022-08-12

Family

ID=76221219

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080084735.0A Pending CN114901267A (zh) 2019-12-05 2020-12-04 酰化活性剂及其用于治疗代谢障碍和非酒精性脂肪肝病的方法

Country Status (8)

Country Link
US (1) US20220296563A1 (https=)
EP (1) EP4069209A4 (https=)
JP (1) JP2023504547A (https=)
CN (1) CN114901267A (https=)
AU (1) AU2020396554A1 (https=)
BR (1) BR112022010672A2 (https=)
CA (1) CA3163342A1 (https=)
WO (1) WO2021113620A1 (https=)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112367987A (zh) * 2018-06-05 2021-02-12 旗舰创业创新五公司 活性剂和其用于治疗代谢障碍和非酒精性脂肪性肝病的方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2258173A1 (en) * 1974-01-22 1975-08-18 Expl Marques Brevets Et Acetylsalicylic acid 2-p-chlorophenoxy isobutyric acid compsns - with anticoagulant and hypocholesterolaemic effects
US4276430A (en) * 1976-12-15 1981-06-30 The Procter & Gamble Company Analgesic and anti-inflammatory compounds and compositions containing same
US4339428A (en) * 1980-08-18 1982-07-13 Bristol-Myers Company Capsule product containing high dosage of aspirin in powder or granulated form and alkaline tablet or pellet comprising magnesium carbonate, calcium carbonate and a magnesium dry component
FR2720936B1 (fr) * 1994-06-08 1997-04-30 Synthelabo Poudres à base de métoclopramide et de paracétamol ou de dérivés d'acide acétylsalicylique.
WO1996016639A1 (en) * 1994-12-01 1996-06-06 Cibus Pharmaceutical, Inc. Nsaid delivery employing a powdered hydrocolloid gum obtainable from higher plants
DE19726871C1 (de) * 1997-06-24 1999-03-04 Werner Kreutz Synergistisch wirkende Zusammensetzungen zur selektiven Bekämpfung von Tumorgewebe
US20090036516A1 (en) * 2003-01-13 2009-02-05 Ctg Pharma S.R.L. Compounds for treating metabolic syndrome
PT2056815E (pt) * 2006-08-16 2013-04-03 Amderma Pharmaceuticals Llc Utilização de derivados de 2,5-dihidroxibenzeno para tratar dermatite
EP2445344A4 (en) * 2009-06-25 2013-01-23 Pozen Inc METHOD FOR THE TREATMENT OF A PATIENT REQUIRED BY ASPIRIN THERAPY
US8834858B2 (en) * 2010-07-02 2014-09-16 Solvotrin Therapeutics Ltd. Treatment for dyslipidemia
US8287904B2 (en) * 2010-08-19 2012-10-16 Lionel Borkan Stable soft capsule dosage form for acetylsalicylic acid
US11771659B2 (en) * 2017-06-19 2023-10-03 The Cleveland Clinic Foundation Treating disease and promoting weight loss by inhibiting the TMA/FMO3/TMAO pathway
EP3801489A4 (en) * 2018-06-05 2022-03-30 Flagship Pioneering Innovations V, Inc. ACYLATED DRUGS AND METHODS OF USE FOR THE TREATMENT OF AUTOIMMUNE DISEASES
JP7645244B2 (ja) * 2019-08-30 2025-03-13 中国科学院動物研究所 代謝性疾患と闘うために使用される組成物およびその組成物の使用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112367987A (zh) * 2018-06-05 2021-02-12 旗舰创业创新五公司 活性剂和其用于治疗代谢障碍和非酒精性脂肪性肝病的方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHENG-WEI LIU 等: "Polyphenol-rich longan (Dimocarpus longan Lour.)-flower-water-extract attenuates nonalcoholic fatty liver via decreasing lipid peroxidation and downregulating matrix metalloproteinases-2 and -9", 《FOOD RESEARCH INTERNATIONAL》, vol. 45, pages 444 - 449, XP028437193, DOI: 10.1016/j.foodres.2011.11.007 *
CHRISTIANE VETTEL 等: "Dopamine and Lipophilic Derivates Protect Cardiomyocytes against Cold Preservation Injury", 《J PHARMACOL EXP THER》, vol. 348, pages 77 - 85 *
张影 等: "阿司匹林治疗非酒精性脂肪肝的双盲研究", 《齐齐哈尔医学院学报》, vol. 36, no. 31, pages 4687 - 4689 *

Also Published As

Publication number Publication date
BR112022010672A2 (pt) 2022-08-16
US20220296563A1 (en) 2022-09-22
AU2020396554A1 (en) 2022-07-07
EP4069209A4 (en) 2024-04-10
CA3163342A1 (en) 2021-06-10
WO2021113620A8 (en) 2021-07-22
EP4069209A1 (en) 2022-10-12
WO2021113620A1 (en) 2021-06-10
JP2023504547A (ja) 2023-02-03

Similar Documents

Publication Publication Date Title
JP7592140B2 (ja) 代謝障害および非アルコール性脂肪肝疾患の治療のための活性薬剤およびその使用方法
KR101986272B1 (ko) 삼환식 화합물, 이를 포함하는 조성물 및 그의 용도
CN119241632A (zh) 雷公藤红素的类似物
CA2873104A1 (en) Compositions and methods for the treatment of mucositis
WO2010040286A1 (zh) 三乙酰基-3-羟基苯基腺苷及其调血脂的用途
JP2018509474A (ja) インダン酢酸誘導体を用いる肝疾患の治療方法
JP2017531649A (ja) 多発性硬化症の治療のための組成物及び方法
US20220204468A1 (en) Dp antagonist
US20260001872A1 (en) Benzisothiazole compound and application thereof, and pharmaceutical composition and application thereof
US9102636B2 (en) Analgesic compounds, compositions, and uses thereof
CN119350175B (zh) 一类新型酰基苯丙氨酸衍生物、其制备方法及其作为药物的用途
JP7498504B2 (ja) 脳神経または心臓保護剤としてのアミノチオール系化合物の使用
CN114901267A (zh) 酰化活性剂及其用于治疗代谢障碍和非酒精性脂肪肝病的方法
US20220296555A1 (en) Acylated active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease
RU2749188C2 (ru) Композиции и способы лечения желудочно-кишечных полипов
JP2005500994A (ja) 医薬活性のある化合物及び使用方法
AU2008257319B2 (en) Use of 4-cyclopropylmethoxy-N-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for the treatment of cranial traumas
JP2022532186A (ja) 非晶質のｐｉ３ｋ阻害剤及びこれを含有する医薬組成物
CN101735218A (zh) 哌啶氨基甲酸酯衍生物及其应用
EP4506346A1 (en) Thiobenzimidazole derivative or pharmaceutically acceptable salt thereof, and use thereof
ES2694110T3 (es) Fármaco profiláctico o terapéutico para el estreñimiento
KR101048748B1 (ko) 신규 갈바닉산 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 다약제내성 억제용 약학적 조성물
CN106459053B (zh) 吡唑并[3,4-d]嘧啶-4-酮衍生物、其制备方法和应用
JPH0228113A (ja) 高尿酸血症改善・治療剤
CN102358731A (zh) 2-取代-6,7-二甲氧基四氢异喹啉衍生物，其制备方法，药物组合物及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20220812

RJ01 Rejection of invention patent application after publication